Drugs in MeSH Category Carcinogens

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tablicaps	STILBESTROL	diethylstilbestrol	TABLET, DELAYED RELEASE;ORAL	083007-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	STILBETIN	diethylstilbestrol	TABLET;ORAL	004056-008	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	STILBETIN	diethylstilbestrol	TABLET, DELAYED RELEASE;ORAL	004056-014	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	STILBETIN	diethylstilbestrol	TABLET;ORAL	004056-010	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class “Carcinogens”

Last updated: July 9, 2026

What is the NLM MeSH “Carcinogens” class and why does it matter for IP and market dynamics?

The NLM MeSH category Carcinogens is not a single drug class with uniform chemistry, regulatory pathways, or patent patterns. It is a topic taxonomy used in biomedical indexing and literature search. In patent and commercial terms, the “Carcinogens” MeSH tag functions more like a therapeutic and exposure concept umbrella than a consistent regulatory grouping.

Business impact

• Patent estates mapped to “carcinogens” MeSH concepts often span chemoprevention, risk reduction, therapy for malignancies caused by carcinogens, and detoxification or exposure-management interventions rather than one shared platform (small molecule, biologic, or device).
• Market size is driven by incidence of carcinogen-linked cancers, screening adoption, and public health policy, not only drug efficacy.
• IP risks typically cluster around secondary patents (formulations, combinations, dosing regimens, biomarkers, method-of-use) because primary active ingredient patents are often owned by legacy or platform portfolios.

Which drug categories show up under “carcinogens” MeSH in practice?

Featured MeSH-driven search behavior tends to pull in three categories:

1) Chemoprevention and risk reduction

• Interventions used to reduce cancer risk in high-risk populations tied to carcinogenic exposures (tobacco, aflatoxins, asbestos, UV, chronic inflammation proxies).
• IP estates often emphasize method-of-use and biomarker-defined populations.

2) Cancer therapies for carcinogen-associated malignancies

• Standard oncology drugs used for cancers where a carcinogen is a known or suspected etiology.
• IP estates are dominated by indication-specific method-of-use, combination regimens, and line-of-therapy.

3) Supportive or exposure-related interventions

• Agents aimed at detoxification, mitigation of exposure effects, or management of treatment-related carcinogenic risk.
• Patent coverage is frequently process/manufacturing and formulation dependent.

How do patent estates typically look for drugs tied to carcinogens concepts?

For “carcinogens” MeSH-associated drug development, the most common patent architecture is:

Primary patents

• Composition of matter for an active ingredient (if the active is a dedicated small molecule/biologic).
• Early in life: higher exclusivity concentration in primary IP.

Secondary patents (dominant in many cases)

• Formulation: extended release, nanoparticle/solubilization, fixed-dose combinations, protective coatings.
• Method of use: prevention/therapeutic benefit in a population defined by exposure history or biomarker.
• Combination therapy: specific pairings with checkpoint inhibitors, endocrine therapy, chemotherapy, or targeted agents.
• Dosing regimens: schedule and titration tied to toxicity management.
• Manufacturing and process: sterile processes, controlled crystal form, impurities profile.

Portfolio-level effect

• Many “carcinogens” concept-linked products rely on layering of method-of-use and regimen patents to extend commercial exclusivity after base compound expiry.

When do drugs associated with “carcinogens” lose exclusivity, and what determines the timeline?

Exclusivity outcomes depend on whether the product is:

• A new chemical entity with Orange Book exclusivity (small molecule) or
• A biologic with BLA exclusivity and a different patent-to-approval structure.

Key timing drivers:

• Composition of matter expiry for the active.
• Indication-specific method-of-use patents still in force.
• FDA exclusivity (if applicable) and the pediatric exclusivity layer.
• Patent term adjustments that shift listed expiration dates.
• Switchovers from one formulation to another (line extensions can create new protected SKUs).

What is the Orange Book status of “carcinogens” MeSH drugs?

MeSH alone does not map cleanly to Orange Book listings. The Orange Book status is product-specific and requires linking the MeSH concept to a specific FDA-approved drug.

How many patents typically cover “carcinogens” MeSH-related products?

In practice, products associated with prevention or carcinogen-linked oncology often carry multiple concurrent patent families:

• 1-2 composition-of-matter families
• 3-10 method-of-use and combination families
• 1-5 formulation/form factor families
• additional manufacturing/process patents

When counsel and investors evaluate “carcinogens” concept-linked portfolios, they usually underwrite secondary IP resilience, not only base expiry.

Which companies control the patent estates for carcinogen-related drugs?

Control is split across:

• Incumbent pharma owning the active ingredient and initial indication approvals.
• Biotech holding companion diagnostics-linked method-of-use patents.
• Generic and biosimilar entrants that often file challenges once a predictable exclusivity or base patent expiry date is visible.

Which companies are challenging patents for carcinogen-related drug products via Paragraph IV?

Paragraph IV strategies typically target:

• The earliest-expected exclusivity break tied to base compound patents.
• Indication-specific method-of-use patents that appear more contestable due to narrow claim scope.

Paragraph IV patterns depend on the individual product’s Orange Book listings and litigation history; MeSH classification alone does not predict challengers or filing counts.

What patent litigation affects drug products tied to carcinogens concepts?

Common litigation themes:

• Claim construction disputes on method-of-use and dosing claims.
• Written description and enablement challenges for regimen or population definitions.
• Indefiniteness challenges where claim language uses biomarker thresholds or exposure categories.
• Infringement fights around whether the accused generic’s labeling and regimen fall within the protected method.

In oncology and prevention, settlements often include:

• A carve-out for noninfringing indications,
• Design-around labeling, and
• A delayed launch date for the contested claim set.

How does patent strength differ between chemoprevention and oncology products in carcinogen-linked markets?

Chemoprevention portfolios skew toward method-of-use, biomarker, and population claim scope. That creates:

• Higher litigation risk around clinical claim boundaries.
• Greater value in labeling precision and trial record alignment.

Oncology drug estates skew toward combination regimens and line-of-therapy claims, with:

• Stronger leverage where a regimen is directly copied in generic labeling or is clinically standardized.
• Faster generics pressure when multiple combination regimens exist and claim coverage is narrow to a single pair or schedule.

What formulations are protected in carcinogen-linked drug markets?

Typical protected formulation directions:

• Fixed-dose combinations (e.g., active + partner drug)
• Extended release or altered bioavailability to reduce dosing frequency or improve tolerability
• Solubilization platforms for poorly soluble actives
• Abuse deterrent or patient adherence improvements (more common in preventive regimens)

Formulation patents matter because they can:

• Enable a branded product to retain exclusivity for specific NDCs even after base ingredient expiry.
• Force generics into longer “launch or not launch” timelines pending design-around work.

How does MeSH “Carcinogens” map to biosimilar risk versus generic risk?

• For small molecules, the risk is mainly ANDA Paragraph IV litigation against Orange Book patents.
• For biologics, risk is BLA biosimilar development plus patent disputes under the biosimilar framework.
• Biologics often face fewer “regimen labeling carve-outs” and more pressure on process comparability and structural similarity.

MeSH tagging does not substitute for product-by-product patent listing analysis, but the risk framework follows standard small molecule vs biologic patterns.

What generic entry risks exist for drugs connected to carcinogens concepts?

Generic entry risk is driven by:

• Number of unexpired patents listed for the product,
• Strength and breadth of method-of-use and formulation claims,
• Whether the marketed generic could lawfully omit the protected method from labeling.

In carcinogen-linked prevention markets, the generic can sometimes launch with “non-protected” claims, but that requires labeling strategy alignment. In oncology, because standard of care is guideline-driven, generics face more practical label pressure.

How do combination regimens change the patent and launch landscape?

Combination therapy often produces:

• Multiple overlapping patents, one per component, plus regimen-specific patents for the combination and schedule.
• Higher settlement frequency because infringement arguments are easier to make when the generic adopts a near-identical regimen in label language.

From a market dynamics perspective:

• Combination brands hold pricing power longer by using layered IP and clinical pathway control.
• Loss of exclusivity in one component does not always break the protected combination if method-of-use or co-administration claims remain in force.

What is the commercial exposure of major “carcinogens” concept-driven oncology and prevention products?

Commercial exposure cannot be quantified from MeSH taxonomy alone without anchoring to specific FDA-approved products, revenue, and NDC-level sales. Patent strategy in these areas is still typically underwritten with:

• Maximum protected SKU revenue during exclusivity
• Expected erosion curve after first allowed generic entry
• Additional erosion delays if formulation or method patents block early launches

How to evaluate the patent estate for a carcinogen-linked drug: a practical checklist

For diligence, the evaluation framework is:

• Identify the active ingredient platform and whether the key claims are composition or method-of-use.
• Map the Orange Book / patent listing families to:
  • formulation
  • method-of-use
  • combination regimens
  • manufacturing/process
• Anchor the earliest unexpired “but for” patent that blocks generic labeling or product approval.
• Track whether litigation is about:
  • validity (written description, enablement, obviousness)
  • infringement (labeling/regimen)
  • procedural (timing, stays, scope of settlement)

Key Takeaways

• NLM MeSH “Carcinogens” is a concept taxonomy, not an IP grouping; patent and market dynamics must be built product-by-product.
• The dominant IP pattern for carcinogen-linked prevention and oncology is layered secondary patents: method-of-use, biomarkers/exposure-defined populations, and combination regimens.
• Exclusivity timelines are driven by listed patents and FDA exclusivity, not by MeSH classification.
• Generic and biosimilar risk is highest where method-of-use and formulation patents are narrow enough to design around, but combination regimens often preserve longer protection via labeling and regimen alignment.
• Litigation and settlements in these markets frequently hinge on labeling scope and regimen equivalence, not only the base active ingredient.

FAQs

1. How do exposure-history defined method-of-use patents impact generic labeling for carcinogen-linked chemoprevention?
2. What patent families most often delay generic launches for oncology combination regimens tied to carcinogen etiology?
3. How does patent term adjustment affect the practical “first generic” date for method-of-use claims?
4. What role do formulation patents play in extending exclusivity at the NDC level after base patent expiry?
5. How do settlement agreements in Paragraph IV cases typically allocate launch timing across multiple listed patent families?

References

1. NLM. MeSH Browser. “Carcinogens.” National Library of Medicine. (Accessed July 9, 2026).